Sorin Group Announces First U.S. Implant of PARADYM RF SonR CRT-D for RESPOND CRT IDE Clinical TrialJune 20, 2013 10:00 am | by Business Wire | Comments
Sorin Group (MIL:SRN), a global medical device company and leader in the treatment of cardiovascular diseases, announces the first U.S. implant of its PARADYM SonR CRT System for the RESPOND CRT IDE Clinical Trial. Dr. B. A. Smith, Electrophysiologist, Piedmont Heart Institute, Atlanta, GA, performed the procedure on May 30.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a new algorithm that can accurately measure the heart rates of people depicted in ordinary digital video by analyzing imperceptibly small head movements that accompany the rush of blood caused by the heart’s contractions.
Product development firm Cambridge Consultants has announced that it is working with the Institute of Metabolic Science (IMS) at Addenbrooke’s Hospital in Cambridge, UK on groundbreaking research to create an artificial pancreas.
Covidien (NYSE: COV), a leading global provider of healthcare products, has announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.
For less than $100, University of Washington researchers have designed a computer-interfaced drawing pad that helps scientists see inside the brains of children with learning disabilities while they read and write.
Shares of Medtronic slipped Tuesday, a day after the medical device maker announced findings from independent reviews of studies of its Infuse bone graft. The Minneapolis company said the reviews, conducted through Yale University, concluded that clinical success rates with its Infuse product were equivalent to more traditional bone graft procedures in which bone is taken from the hip.
For a long time, heat insulation was en vogue – and nearly no one was concerned about poor indoor air quality. And yet excess CO2 hampers concentration. Now, researchers have come up with an intelligent door seal system.
3D printing can now be used to print lithium-ion microbatteries the size of a grain of sand. The printed microbatteries could supply electricity to tiny devices in fields from medicine to communications, including many that have lingered on lab benches for lack of a battery small enough to fit the device, yet provide enough stored energy to power them.
Aesculap Implant Systems recently introduced the CeSpaceXP Interbody System for ACDF procedures. The CeSpaceXP fuses two proven materials, an innovative Plasmapore®XP osteoconductive porous Titanium coating and a PEEK-Optima® radiolucent core, that delivers enhanced implant stability, artifact-free imaging, and an optimal scaffold for cervical fusion procedures.
OrthoSensor has announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VERASENSE Knee System with limb alignment. VERASENSE is the first intraoperative instrument system to combine quantifiable data on limb alignment, implant position and soft tissue balancing for surgeons during total knee replacement surgery.
Surgical Theater’s Surgical Rehearsal Platform (SRP) provided neurosurgeons the opportunity to rehearse a complicated cerebral case before entering the operating room, saving the surgical team critical seconds on a time-sensitive procedure.
Foster Corporation has introduced ProPell thermoplastic polyurethane (TPU) and polyether block amide (PEBA) compounds for improved manufacturing and handling of medical catheters.
Systems such as a beating heart or a power grid that depend on the synchronized movement of their parts could fall prey to an invisible and chaotic tug-of-war known as a "chimera."
St. Jude Medical (NYSE:STJ) has announced U.S. Food and Drug Administration (FDA) approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery.